AAV analysis by sedimentation velocity analytical ultracentrifugation: beyond empty and full capsids

被引:13
|
作者
Yarawsky, Alexander E. [1 ]
Zai-Rose, Valeria [1 ]
Cunningham, Hazel M. [1 ]
Burgner II, John W. [1 ,2 ]
DeLion, Michael T. [1 ]
Paul, Lake N. [1 ]
机构
[1] BioAnalysis LLC, 3401 1 St Suite 206, Philadelphia, PA 19134 USA
[2] Virginia Commonwealth Univ, Sch Pharm, Dept Med Chem, 800 East Leigh St, Richmond, VA 23298 USA
关键词
Adeno-associated viral vectors; cGMP; SEDFIT; Wide distribution analysis; Time derivative; Partial capsids; COEFFICIENT DISTRIBUTION; SIZE-DISTRIBUTION; DISTRIBUTIONS; MACROMOLECULES; QUANTIFICATION; SEPARATION;
D O I
10.1007/s00249-023-01646-z
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The recent surge of therapeutic interest in recombinant adeno-associated viral (AAV) vectors for targeted DNA delivery has brought analytical ultracentrifugation (AUC) into the spotlight. A major concern during formulation of AAV therapeutics is purity of the active species (DNA-containing capsid, or "filled capsids"). Insertion of DNA into AAV is not a highly efficient process; thus, a significant amount of empty and partial/intermediate AAV molecules may exist. Recent guidance from the FDA includes limiting the presence of empty AAV capsids and other impurities to reduce immunotoxicity. While chromatographic techniques (SEC, SEC-MALS, AEX) are often used for empty and full capsid quantitation due to the ease of accessibility and familiarity among most biochemists, the resolution and sensitivity attained by sedimentation velocity (SV-AUC) in the formulation buffer and purification buffers is unmatched. Approaches for using SV-AUC to determine the empty-to-full capsid ratio have already been discussed by others; however, in this report, we focus on the importance of characterizing other impurities, such as free DNA, partially filled capsids, and aggregates that are recognized as species of concern for immunotoxicity. We also demonstrate the usefulness of applying multiple analyses (e.g., c(s), g(s*), WDA) in confirming the presence of and determining the hydrodynamic parameters of these various species.
引用
收藏
页码:353 / 366
页数:14
相关论文
共 50 条
  • [11] Chromatographic separation of full and empty AAV8 capsids
    Leskovec, M.
    HUMAN GENE THERAPY, 2017, 28 (12) : A108 - A109
  • [12] Sedimentation Velocity Analytical Ultracentrifugation of Oxidized Recombinant Full-Length Factor VIII
    Zakas, Philip M.
    Healey, John F.
    Smith, Ian W.
    Lillicrap, David
    Lollar, Pete
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [13] On the analysis of protein self-association by sedimentation velocity analytical ultracentrifugation
    Schuck, P
    ANALYTICAL BIOCHEMISTRY, 2003, 320 (01) : 104 - 124
  • [14] Sedimentation velocity analytical ultracentrifugation for characterization of therapeutic antibodies
    Uchiyama S.
    Noda M.
    Krayukhina E.
    Biophysical Reviews, 2018, 10 (2) : 259 - 269
  • [15] Purity and DNA content of AAV capsids assessed by analytical ultracentrifugation and orthogonal biophysical techniques
    Richter, Klaus
    Wurm, Christine
    Strasser, Kim
    Bauer, Jana
    Bakou, Maria
    VerHeul, Ross
    Sternisha, Shawn
    Hawe, Andrea
    Salomon, Michael
    Menzen, Tim
    Bhattacharya, Akash
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2023, 189 : 68 - 83
  • [16] Studying multiprotein complexes by multisignal sedimentation velocity analytical ultracentrifugation
    Balbo, A
    Minor, KH
    Velikovsky, CA
    Mariuzza, RA
    Peterson, CB
    Schuck, P
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (01) : 81 - 86
  • [17] Sedimentation Velocity Analytical Ultracentrifugation Analysis of Marketed Rituximab Drug Product Size Distribution
    Sharadrao M. Patil
    John Nguyen
    David A. Keire
    Kang Chen
    Pharmaceutical Research, 2020, 37
  • [18] Sedimentation Velocity Analytical Ultracentrifugation Analysis of Marketed Rituximab Drug Product Size Distribution
    Patil, Sharadrao M.
    Nguyen, John
    Keire, David A.
    Chen, Kang
    PHARMACEUTICAL RESEARCH, 2020, 37 (12)
  • [19] Structural Changes Likely Cause Chemical Differences between Empty and Full AAV Capsids
    Heldt, Caryn L.
    Skinner, Molly A.
    Anand, Ganesh S.
    BIOMEDICINES, 2024, 12 (09)
  • [20] Strategies in AAV Upstream Process and Downstream Purification for High Yield and High Separation of AAV Empty and Full Capsids
    Mallory, Heather
    Liu, Xiaojun
    Jiang, Jun
    Zhu, Jing
    Zhang, Jason
    MOLECULAR THERAPY, 2021, 29 (04) : 400 - 400